Lupin Limited has entered into an exclusive licensing agreement with U.S.-based biosimilar specialist Valorum Biologics for the commercial rollout of its biosimilar Armlupeg™ (pegfilgrastim-unne) in the United States.
The partnership brings together Lupin’s proven manufacturing capabilities and Valorum’s focused expertise in U.S. biosimilar commercialization.
Under the agreement, Valorum will take charge of commercialization and distribution of Armlupeg™ across the U.S. market, while Lupin will continue to handle the manufacturing and supply of the product. As part of the commercial terms, Lupin is set to receive an upfront licensing fee, followed by royalty payments based on net sales, strengthening the company’s U.S. biosimilar revenue stream.
Pegfilgrastim-unne, the active ingredient in Armlupeg™, is prescribed to reduce the duration of neutropenia and lower the risk of febrile neutropenia in patients undergoing chemotherapy. With cancer care in the U.S. increasingly focused on affordable and reliable biologic alternatives, this collaboration positions Armlupeg™ as a strong contender in the pegfilgrastim biosimilar category.
The agreement underscores Lupin’s intention to expand its biosimilar footprint in global markets, while giving Valorum a high-value asset to strengthen its oncology-supportive care portfolio.
